An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
Authors
Lenard A. Adler (ORCID: https://orcid.org/0000-0002-9812-8234)
Zulane Maldonado-Cruz
Ann Catherine Childress (ORCID: https://orcid.org/0000-0001-5782-7891)
Nicholas Fry
Andrea E. Formella (ORCID: https://orcid.org/0000-0003-2737-7898)
Kobby Asubonteng
Jonathan Rubin (ORCID: https://orcid.org/0000-0003-4344-4587)
Andrew J. Cutler (ORCID: https://orcid.org/0000-0001-5800-0378)
Institutions
SUNY Upstate Medical University (US)
Supernus Pharmaceuticals (United States) (US)
Center for Psychiatry and Behavioral Medicine (US)
An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
Lenard A. Adler, Zulane Maldonado-Cruz, Ann Catherine Childress, Nicholas Fry et al.
Citations
3 citations
Journal
CNS Drugs
Topics
Attention Deficit Hyperactivity Disorder
Field-Weighted Citation Impact (FWCI)
1.16
article
An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
Lenard A. Adler, Zulane Maldonado-Cruz, Ann Catherine Childress, Nicholas Fry, Andrea E. Formella, Kobby Asubonteng, Jonathan Rubin, Andrew J. Cutler
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
CNS DrugsVol. 38(11)
Institutions
SUNY Upstate Medical University (US), Supernus Pharmaceuticals (United States) (US), Center for Psychiatry and Behavioral Medicine (US), New York University (US)